Otonomy Suspends Development of Lead Drug After Phase III Flop, Stock Plunges Post author:Sam Post published:August 29, 2017 Post category:BioPharma August 30, 2017By Alex Keown, BioSpace… Source: BioSpace You Might Also Like Medpace Reports Fourth Quarter And Full Year 2016 Results February 27, 2017 Cambridge's 30-Person to Dissolve This Week June 4, 2017 Ex-Employees Accuse Biotech Hedge Fund Founder of Toxic Sexual Harassment Culture December 5, 2017
